Today: 22 November 2025
Subscribe
Browse Category

Pharmaceuticals News 30 October 2025 - 5 November 2025

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Financial Health and Earnings Trends Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quarters investing.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY (1% in constant currency) to $4.48 B investing.com, while adjusted earnings jumped to $0.78 per share (from $0.69 a year ago) reuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025 reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection
5 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value reuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic (both containing the GLP-1 agonist semaglutide) became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth story stockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date
5 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share reuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performance reuters.com reuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal” reuters.com. This was weeks
4 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Q3 Earnings Beat and Raised Outlook Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensus (~$0.63–$0.64) reuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecasts (~$16.5B) stocktwits.com reuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates. Encouraged by the quarter’s results,
4 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) sharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirations sharewise.com. By mid-2025, Pfizer traded near multi-year lows (around $23), though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 (from ~$23.85 on Sept. 29 to ~$27.37 by
3 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

RANI Stock Performance: From Penny Stock to Momentum Rocket Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one day finviz.com on massive volume (~61 million shares vs ~15 million average finviz.com). In fact, over the past month RANI has climbed about 335% finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating
3 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering the first approved COVID-19 vaccine, Pfizer’s innovations have had global impact. Today the company employs about 81,000 people worldwide and operates 35+ manufacturing sites xtalks.com. It was the world’s top drugmaker by sales during the pandemic boom (record revenue of $100 billion in 2022), and even with post-COVID declines Pfizer is expected to generate ~$62 billion in revenue in 2025
2 November 2025
 ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Market Snapshot (pre-market Nov 3) As of Oct. 31 close, Eli Lilly (NYSE:LLY) was around $862–864 (with after-hours ~864) stockanalysis.com marketbeat.com. That’s up ~9–10% from early October nasdaq.com. Trading volumes have been heavy, and LLY remains near its 52-week high (~$935) marketbeat.com. MarketBeat notes LLY’s 50-day moving average is ~$780 marketbeat.com, reflecting the recent surge. Institutional ownership is high (~82.5% by funds marketbeat.com) and sentiment is bullish. Blowout Q3 & Raised Guidance Lilly’s Q3 (announced Oct 30) blew past forecasts. Revenue was $17.60 billion (+54% YoY) with EPS $7.02 marketbeat.com, versus consensus ~$16.1 B/$5.9. Key GLP-1 drugs led the surge. The company
2 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Stock Performance and Recent Movement Rani shares have exploded in the last month. On Oct 1, 2025 RANI traded around $0.50. A landmark collaboration announced Oct 17 with Japan’s Chugai (up to $1.085B deal) and a simultaneous $60M financing sent the stock soaring. Intraday Oct 17 it jumped from $0.47 to $2.39 (+248%) ts2.tech. By Oct 31 the stock closed at $2.20, a 51.7% gain on that day alone ts2.tech. This means RANI is up roughly +20% in the past week (from ~$1.82 on Oct 24 to $2.20) and about +330% in October investing.com investing.com.This rally propelled RANI well above
1 November 2025
 ·  ·  ·  ·  · 
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

Stock Performance & Technical Trends AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on record ts2.tech reportify.cn. This vastly outperforms both the S&P 500 (up ~16% YTD) and the broader pharma industry (up mid-single-digits) timesunion.com reportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1st ts2.tech. Several catalysts have fueled this rally. In mid-September, AbbVie announced a patent settlement securing no U.S. generics
31 October 2025
 ·  ·  ·  ·  · 
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Market Performance & Buyout Rumors On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56 tradingview.com, reversing much of September–October’s slide. This followed a STAT News report (cited by Reuters) that Moderna has held buyout or partnership talks with at least one large drugmaker tradingview.com. Moderna’s shares had been languishing near all-time lows (after falling roughly 90% from pandemic highs) tradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 price tradingview.com. (By comparison, the Nasdaq and biotech indices were
30 October 2025
 ·  ·  ·  ·  · 
1 … 3 4 5 6 7 … 10
Go toTop